Megan Humphreys

Megan Humphreys serves as Vice President of Corporate Communications for Evommune. She has nearly 20 years of experience in corporate affairs and communications across biotechnology, pharmaceutical, and other highly regulated industries. Prior to joining Evommune, Megan was Head of Corporate Affairs and Public Affairs at RayzeBio (acquired by Bristol Myers Squibb), and Head of Communications at Mirati Therapeutics (acquired by Bristol Myers Squibb), guiding the company through the launch of KRAZATI®, significant clinical and corporate milestones, and its acquisition by Bristol Myers Squibb. Earlier in her career, she held senior communications and public affairs roles at Spectrum Science, Signal Group and other agencies, advising biotechnology and pharmaceutical companies across stages of development. She also founded and led Convé Communications, a boutique life sciences communications consultancy. Megan earned her Masters in Public Relations and International Relations from the S.I Newhouse School of Public Communications and the Maxwell School of Citizenship and Public Affairs at Syracuse University.